Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
- PMID: 37211049
- DOI: 10.1016/j.ijcard.2023.05.032
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
Abstract
Background: Heart failure (HF) is associated with poor health status, and high morbi-mortality. However, it is not well established how health status changes correlate with treatment effects on clinical outcomes. Our aim was to study the association between treatment-induced changes in health-status, assessed by Kansas City Cardiomyopathy Questionnaire 23 (KCCQ-23), and clinical outcomes in chronic HF.
Methods: Systematic search of phase III-IV pharmacological RCTs in chronic HF that assessed KCCQ-23 changes and clinical outcomes throughout follow-up. We studied the association between treatment induced changes in KCCQ-23 and treatment effects on clinical outcomes (HF hospitalization or cardiovascular death, HF hospitalization, cardiovascular death, and all-cause death) using weighted random-effects meta-regression.
Results: Sixteen trials were included, enrolling a total of 65,608 participants. Treatment induced KCCQ-23 changes were moderately correlated with treatment effects on the combined outcome of HF hospitalization or cardiovascular mortality (regression coefficient (RC) = -0.047, 95%CI: -0.085 to -0.009; R2 = 49%), a correlation that was mainly driven by HF hospitalization (RC = -0.076, 95%CI: -0.124 to -0.029; R2 = 56%). Correlations of treatment induced KCCQ-23 changes with cardiovascular death (RC = -0.029, 95%CI: -0.073 to 0.015; R2 = 10%) and all-cause death (RC = -0.019, 95%CI: -0.057 to 0.019; R2 = 0%) were weak and non-significant.
Conclusions: Treatment-induced changes in KCCQ-23 were moderately correlated with treatment-effects on HF hospitalizations but were not correlated with the effects on cardiovascular and all-cause mortality. Treatment-induced changes in patient-centered outcomes (i.e., KCCQ-23) may reflect non-fatal symptomatic changes in the clinical course of HF leading to hospitalization.
Keywords: Health status; Heart failure; Hospitalization; KCCQ; Mortality.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest JPF is a consultant for Boehringer-Ingelheim, Astra-Zeneca and Novartis and has received research support from Astra-Zeneca, Novartis and Bayer through his institution, the University of Porto. JB is a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana Medical, and Vifor Pharma. MP has been a consultant to Abbvie, Altimmune, Amarin, Amgen, Ardelyx, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Moderna, Novartis, Reata, Relypsa, Salamandra. All other authors report not having relevant conflicts of interest regarding this work.
Similar articles
-
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.JAMA Cardiol. 2017 Dec 1;2(12):1315-1321. doi: 10.1001/jamacardio.2017.3983. JAMA Cardiol. 2017. PMID: 29094152 Free PMC article.
-
Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.Eur J Heart Fail. 2019 Jan;21(1):63-70. doi: 10.1002/ejhf.1299. Epub 2018 Aug 31. Eur J Heart Fail. 2019. PMID: 30168635 Free PMC article. Clinical Trial.
-
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.JAMA Cardiol. 2021 May 1;6(5):522-531. doi: 10.1001/jamacardio.2021.0372. JAMA Cardiol. 2021. PMID: 33760037 Free PMC article.
-
Predictive value of quality of life as measured by KCCQ in heart failure patients: A meta-analysis.Eur J Clin Invest. 2024 Sep;54(9):e14233. doi: 10.1111/eci.14233. Epub 2024 Apr 26. Eur J Clin Invest. 2024. PMID: 38666585
-
The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials.Int J Clin Pharm. 2023 Jun;45(3):547-555. doi: 10.1007/s11096-022-01504-6. Epub 2023 Feb 17. Int J Clin Pharm. 2023. PMID: 36800144 Review.
Cited by
-
Factors Associated with Clinically Important Changes in Quality of Life of Heart Failure Patients: The QUALIFIER Prospective Cohort Study.J Clin Med. 2025 Jul 17;14(14):5079. doi: 10.3390/jcm14145079. J Clin Med. 2025. PMID: 40725770 Free PMC article.
-
Recent highlights on myocarditis and cardiomyopathies from the International Journal of Cardiology and International Journal of Cardiology: Heart & Vasculature.Int J Cardiol Heart Vasc. 2023 Nov 27;49:101315. doi: 10.1016/j.ijcha.2023.101315. eCollection 2023 Dec. Int J Cardiol Heart Vasc. 2023. PMID: 38076350 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous